Esperion Therapeutics, Inc.
John B. Harlow, Jr.
Esperion Therapeutics, Inc.
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About John B. Harlow, Jr.
Esperion Therapeutics, Inc. reported in an 8-K filed November 4, 2025 that John B. Harlow, Jr. was appointed Chief Commercial Officer, effective November 17, 2025.
“On November 4, 2025, the board of directors (the “Board”) of Esperion Therapeutics, Inc. (the “Company”) appointed John B. Harlow, Jr. as the Company’s Chief Commercial Officer pursuant to the terms of an employment agreement with Mr. Harlow (the “Harlow Agreement”), effective as of November 17, 2025 (the “Commencement Date”).”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Esperion Therapeutics, Inc.
SEC 8-K
Current2025-11-17–present
Company network
Recorded roles and call appearances connecting this person to public companies.
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.